Abstract:Key PointsAttempts to target RAS pharmaceutically have not yet yielded small molecules with sufficient potency and drug-like characteristics to be useful, but additional approaches are underway.Inhibitors of RAS membrane interaction and subcellular localization remain attractive targets for therapeutic intervention. In this regard, recent discoveries of functionally relevant post-translational modifications of RAS, such as phosphorylation and ubiquitylation, suggest new opportunities to block RAS function.Inhibitors of RAS effector signalling are currently centred on the RAF–MEK–ERK and PI3K–AKT–TOR pathways, with many inhibitors of components of these two pathways under clinical evaluation. The less well-studied effector pathways that lead to activation of RAL and RAC small GTPases are also promising targets.Despite some setbacks owing to issues of reproducibility, functional screens for synthetic lethal interactors with oncogenic RAS remain an attractive approach to identify novel drug targets for RAS-driven cancers.RAS-driven cancers become efficient scavengers of nutrients and may rely on pathways such as autophagy and macropinocytosis. Furthermore, oncogenic KRAS has a crucial role in altering tumour metabolism, including rewiring of both glucose- and glutamine-dependent metabolic pathways. These alterations could provide the opportunity for novel therapeutic interventions.Inhibitors of RAS membrane interaction and subcellular localization remain attractive targets for therapeutic intervention. In this regard, recent discoveries of functionally relevant post-translational modifications of RAS, such as phosphorylation and ubiquitylation, suggest new opportunities to block RAS function.RAS-driven cancers become efficient scavengers of nutrients and may rely on pathways such as autophagy and macropinocytosis. Furthermore, oncogenic KRAS has a crucial role in altering tumour metabolism, including rewiring of both glucose- and glutamine-dependent metabolic pathways. These alterations could provide the opportunity for novel therapeutic interventions.

Combinatorial strategies to target RAS-driven cancers

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

RAS-targeted therapies: is the undruggable drugged?

The current state of the art and future trends in RAS-targeted cancer therapies

RAS‐targeted cancer therapy: Advances in drugging specific mutations

Targeting KRAS in cancer

Emerging strategies to target RAS signaling in human cancer therapy

Finding the sweet spot: Targeting RAS in tumors while sparing normal tissue

Combinations of RAS pathway inhibitors with targeted agents are active in spheroids of patient-derived cells with oncogenic KRAS variants from multiple cancer types

Rationale for RAS mutation-tailored therapies

Drugging the undruggable RAS: Mission Possible?

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

KRAS mutation: from undruggable to druggable in cancer

Targeting KRAS Mutant Cancers: from Druggable Therapy to Drug Resistance

Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives

Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers

Eliminating oncogenic RAS: back to the future at the drawing board

Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies

Resistance Looms for KRAS G12C Inhibitors and Rational Tackling Strategies.

A combinatorial strategy for treating KRAS-mutant lung cancer

Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions